DK2849782T3 - Bacteriophag lysin og antibiotiske sammensætninger imod gram-positive bakterier - Google Patents
Bacteriophag lysin og antibiotiske sammensætninger imod gram-positive bakterier Download PDFInfo
- Publication number
- DK2849782T3 DK2849782T3 DK13787128.1T DK13787128T DK2849782T3 DK 2849782 T3 DK2849782 T3 DK 2849782T3 DK 13787128 T DK13787128 T DK 13787128T DK 2849782 T3 DK2849782 T3 DK 2849782T3
- Authority
- DK
- Denmark
- Prior art keywords
- positive bacteria
- against gram
- compositions against
- antibiotic compositions
- bacteriophage lysine
- Prior art date
Links
- 241000192125 Firmicutes Species 0.000 title 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 title 1
- 239000004472 Lysine Substances 0.000 title 1
- 230000003115 biocidal effect Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 241001515965 unidentified phage Species 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
- A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/085—Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/503—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01017—Lysozyme (3.2.1.17)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Paints Or Removers (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261644944P | 2012-05-09 | 2012-05-09 | |
| US201261737239P | 2012-12-14 | 2012-12-14 | |
| PCT/US2013/040329 WO2013170015A1 (en) | 2012-05-09 | 2013-05-09 | Bacteriophage lysin and antibiotic combinations against gram positive bacteria |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2849782T3 true DK2849782T3 (da) | 2020-06-22 |
Family
ID=49551273
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK13787128.1T DK2849782T3 (da) | 2012-05-09 | 2013-05-09 | Bacteriophag lysin og antibiotiske sammensætninger imod gram-positive bakterier |
Country Status (16)
| Country | Link |
|---|---|
| US (5) | US10813983B2 (enExample) |
| EP (2) | EP2849782B1 (enExample) |
| JP (4) | JP6608697B2 (enExample) |
| KR (3) | KR20210121313A (enExample) |
| CN (1) | CN104736172A (enExample) |
| AU (3) | AU2013259512B2 (enExample) |
| BR (1) | BR112014027842A2 (enExample) |
| CA (1) | CA2872902A1 (enExample) |
| DK (1) | DK2849782T3 (enExample) |
| ES (1) | ES2784136T3 (enExample) |
| HK (1) | HK1211484A1 (enExample) |
| IL (3) | IL308477A (enExample) |
| IN (1) | IN2014MN02437A (enExample) |
| MX (2) | MX389127B (enExample) |
| RU (2) | RU2018121290A (enExample) |
| WO (1) | WO2013170015A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2646102C2 (ru) | 2012-05-09 | 2018-03-01 | Контрафект Корпорейшн | Предотвращение, разрушение и обработка биопленки лизином бактериофага |
| AU2013259512B2 (en) | 2012-05-09 | 2018-01-25 | Contrafect Corporation | Bacteriophage lysin and antibiotic combinations against gram positive bacteria |
| BR112016030580B1 (pt) * | 2014-06-26 | 2023-12-19 | The Rockefeller University | Polipeptídeo de lisina e fragmento de polipeptídeo com atividade para matar bactérias gram-negativas |
| WO2016142445A2 (en) * | 2015-03-12 | 2016-09-15 | Micreos Human Health B.V. | A method of treatment of a bacterial infection |
| ES2934714T3 (es) * | 2015-09-17 | 2023-02-24 | Contrafect Corp | Polipéptidos de lisina activos contra bacterias Gram-negativas |
| CN109152822B (zh) * | 2016-05-12 | 2023-12-05 | 抗非特公司 | 用于评估和确定抗菌多肽的最小抑制浓度的肉汤微量稀释法 |
| CA3067542A1 (en) * | 2017-06-19 | 2018-12-27 | Syddansk Universitet | Bacitracin and/or daptomycin combined with cannabidiol for treatment of bacterial infections |
| RU2020104587A (ru) * | 2017-07-10 | 2021-08-10 | Контрафект Корпорейшн | Потенцирование компонентами крови антибактериальной активности литических белков, соответствующие способы и применения |
| CN112118861A (zh) * | 2018-02-26 | 2020-12-22 | 康特拉费克特公司 | 修饰的PlySs2溶素及其用途 |
| MX2020013935A (es) * | 2018-06-22 | 2021-03-09 | Contrafect Corp | Lisinas y sus derivados que resensibilizan staphylococcus aureus y bacterias gram positivas a antibioticos. |
| CN109668873B (zh) * | 2018-12-05 | 2021-03-16 | 山东恒业生物技术有限公司 | 一种活载体疫苗活性检测装置及其使用方法 |
| US12427174B2 (en) * | 2019-02-05 | 2025-09-30 | Biomedit, Inc. | Probiotic compositions comprising lactobacillus reuteri strains and methods of use |
| EP3941504A4 (en) * | 2019-03-22 | 2022-12-07 | Contrafect Corporation | METHOD FOR TREATING INFECTIOUS ENDOCARDITIS |
| AU2020271116A1 (en) * | 2019-04-11 | 2021-11-11 | Contrafect Corporation | Method of treating and preventing bone and joint infections |
| CN114845708A (zh) * | 2019-12-19 | 2022-08-02 | 乔治亚州大学研究基金会 | 用于治疗细菌感染和增强抗生素的化合物 |
| US20230277632A1 (en) * | 2020-05-19 | 2023-09-07 | Contrafect Corporation | MODIFIED PlySs2 LYSINS AND ANTIBIOTIC COMBINATIONS FOR USE AGAINST GRAM-POSITIVE BACTERIA |
| RU2755817C1 (ru) * | 2020-07-22 | 2021-09-21 | Федеральное Государственное бюджетное научное учреждение "Федеральный научный центр биологических систем и агротехнологий российской академии наук" | Способ снижения грамположительной микрофлоры в кишечнике птицы |
| KR102528412B1 (ko) * | 2020-09-08 | 2023-05-04 | 클립스비엔씨 주식회사 | 신규한 포도상구균 감염 질환의 예방 또는 치료용 조성물 |
| WO2022261360A1 (en) * | 2021-06-09 | 2022-12-15 | Contrafect Corporation | Plyss2 lysins and variants thereof for use against multidrug resistant gram-positive bacteria |
| CN115105491B (zh) * | 2022-07-08 | 2023-12-22 | 东北农业大学 | 丝氨酸在制备抑制猪链球菌药物中的用途 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU8108587A (en) | 1986-10-08 | 1988-05-06 | David Bernstein | Method for exposing group a streptococcal antigens and an improved diagnostic test for the identification of group a streptococci |
| ZA883887B (en) | 1987-06-10 | 1990-02-28 | Lilly Co Eli | Chromatographic purification process |
| AU734420B2 (en) * | 1996-04-15 | 2001-06-14 | Nymox Corporation | Compositions containing bacteriophages and methods of using bacteriophages to treat infections |
| US5997862A (en) | 1997-10-31 | 1999-12-07 | New Horizons Diagnostics Corporation | Therapeutic treatment of group A streptococcal infections |
| US6248324B1 (en) | 1997-10-31 | 2001-06-19 | Vincent Fischetti | Bacterial phage associated lysing enzymes for treating dermatological infections |
| US6254866B1 (en) | 1997-10-31 | 2001-07-03 | New Horizons Diagnostics Corporation | Use of phage associated lytic enzymes for treating bacterial infections of the digestive tract |
| US20060292135A1 (en) | 1997-10-31 | 2006-12-28 | Lawrence Loomis | Use of bacterial phage-associated lysing proteins for preventing and treating bacterial infections in humans, animals and fowl |
| US6264945B1 (en) | 1997-10-31 | 2001-07-24 | Vincent A Fischetti | Parenteral use of bacterial phage associated lysing enzymes for the therapeutic treatment of bacterial infections |
| JP2002537350A (ja) | 1999-02-25 | 2002-11-05 | ニュー ホライズンズ ダイアグノスティックス インコーポレーティッド | 連鎖球菌感染の予防的及び治療的な処置のための手段 |
| US6056955A (en) | 1999-09-14 | 2000-05-02 | Fischetti; Vincent | Topical treatment of streptococcal infections |
| US6444813B2 (en) | 2000-02-02 | 2002-09-03 | Pharmacia & Upjohn Company | Linezolid-crystal form II |
| EP1501925A4 (en) | 2002-05-17 | 2006-10-25 | New Horizons Diagnostics Corp | IDENTIFICATION OF A LYTIC ENZYME ASSOCIATED WITH A PHAGE TO DETECT AND ELIMINATE RAPIDLY AND SPECIFICALLY BACILLUS ANTHRACIS |
| US7569223B2 (en) | 2004-03-22 | 2009-08-04 | The Rockefeller University | Phage-associated lytic enzymes for treatment of Streptococcus pneumoniae and related conditions |
| US7638600B2 (en) * | 2004-03-24 | 2009-12-29 | The Rockefeller University | Lytic enzymes and spore surface antigen for detection and treatment of Bacillus anthracis bacteria and spores |
| WO2008018854A2 (en) | 2005-06-06 | 2008-02-14 | The Rockefeller University | Bactiophage lysins for bacillus anthracis |
| US7582291B2 (en) | 2005-06-30 | 2009-09-01 | The Rockefeller University | Bacteriophage lysins for Enterococcus faecalis, Enterococcus faecium and other bacteria |
| CN101297034A (zh) | 2005-08-24 | 2008-10-29 | 洛克菲勒大学 | Ply-gbs突变溶素 |
| US20090053149A1 (en) | 2007-08-24 | 2009-02-26 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Surfactant-based antimicrobial solution for inhalation |
| WO2010002959A2 (en) * | 2008-07-03 | 2010-01-07 | The Rockefeller University | A chimeric bacteriophage lysin with activity against staphylococci bacteria |
| KR101016918B1 (ko) | 2009-01-08 | 2011-02-25 | 주식회사 인트론바이오테크놀로지 | 박테리아 특이적 넓은 항균 활성을 갖는 신규한 리신 단백질 |
| EP2539446B1 (en) | 2010-01-25 | 2017-11-01 | Alere Scarborough Inc. | A25 bacteriophage lysin |
| WO2012145530A2 (en) * | 2011-04-20 | 2012-10-26 | Visa International Service Association | Managing electronic tokens in a transaction processing system |
| EP2699689A4 (en) * | 2011-04-21 | 2014-12-17 | Univ Utrecht Holding Bv | STREPTOCOCCUS BACTERIOPHAGEN LYSINE FOR THE TREATMENT OF GRAM-POSITIVE BACTERIA IN PETS AND UTILITIES |
| MX383544B (es) | 2011-04-21 | 2025-03-14 | Univ Rockefeller | Lisinas de bacteriofago de streptococcus para la deteccion y tratamiento de bacterias gram positivas |
| US9016640B2 (en) | 2011-04-22 | 2015-04-28 | Rks Design, Inc. | Instrument retention assembly |
| US20140120074A1 (en) | 2011-04-27 | 2014-05-01 | Lysando Ag | Antimicrobial agents |
| AU2013259512B2 (en) | 2012-05-09 | 2018-01-25 | Contrafect Corporation | Bacteriophage lysin and antibiotic combinations against gram positive bacteria |
| RU2646102C2 (ru) * | 2012-05-09 | 2018-03-01 | Контрафект Корпорейшн | Предотвращение, разрушение и обработка биопленки лизином бактериофага |
-
2013
- 2013-05-09 AU AU2013259512A patent/AU2013259512B2/en not_active Ceased
- 2013-05-09 KR KR1020217031525A patent/KR20210121313A/ko not_active Ceased
- 2013-05-09 WO PCT/US2013/040329 patent/WO2013170015A1/en not_active Ceased
- 2013-05-09 DK DK13787128.1T patent/DK2849782T3/da active
- 2013-05-09 US US14/399,575 patent/US10813983B2/en not_active Expired - Fee Related
- 2013-05-09 BR BR112014027842A patent/BR112014027842A2/pt not_active IP Right Cessation
- 2013-05-09 IL IL308477A patent/IL308477A/en unknown
- 2013-05-09 RU RU2018121290A patent/RU2018121290A/ru unknown
- 2013-05-09 CA CA2872902A patent/CA2872902A1/en active Pending
- 2013-05-09 MX MX2014013586A patent/MX389127B/es unknown
- 2013-05-09 HK HK15112347.8A patent/HK1211484A1/xx unknown
- 2013-05-09 EP EP13787128.1A patent/EP2849782B1/en active Active
- 2013-05-09 JP JP2015511698A patent/JP6608697B2/ja not_active Expired - Fee Related
- 2013-05-09 RU RU2014149351A patent/RU2659208C2/ru active
- 2013-05-09 IL IL235527A patent/IL235527B2/en unknown
- 2013-05-09 KR KR1020237023634A patent/KR20230113404A/ko not_active Withdrawn
- 2013-05-09 CN CN201380036510.8A patent/CN104736172A/zh active Pending
- 2013-05-09 EP EP20158873.8A patent/EP3685851A1/en active Pending
- 2013-05-09 KR KR1020147034614A patent/KR102310387B1/ko not_active Expired - Fee Related
- 2013-05-09 ES ES13787128T patent/ES2784136T3/es active Active
- 2013-06-04 US US13/909,618 patent/US9889181B2/en not_active Expired - Fee Related
- 2013-12-05 IN IN2437MUN2014 patent/IN2014MN02437A/en unknown
-
2014
- 2014-11-07 MX MX2021011843A patent/MX2021011843A/es unknown
-
2017
- 2017-12-20 US US15/848,886 patent/US20180221456A1/en not_active Abandoned
-
2018
- 2018-04-24 AU AU2018202845A patent/AU2018202845B2/en not_active Ceased
- 2018-04-27 JP JP2018086685A patent/JP2018138045A/ja not_active Withdrawn
-
2019
- 2019-12-06 JP JP2019221319A patent/JP2020054370A/ja active Pending
-
2020
- 2020-05-21 IL IL274832A patent/IL274832A/en unknown
- 2020-09-16 AU AU2020233683A patent/AU2020233683A1/en not_active Abandoned
- 2020-09-25 US US17/033,195 patent/US20210008175A1/en not_active Abandoned
-
2021
- 2021-01-05 US US17/141,692 patent/US20210128696A1/en not_active Abandoned
-
2022
- 2022-01-20 JP JP2022007043A patent/JP2022058682A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL274832A (en) | Combinations of bacteriophage lysine and antibiotics against gram-positive bacteria | |
| DK3628161T3 (da) | Synergistiske bakterielle sammensætninger og fremgangsmåder til fremstilling og anvendelse deraf | |
| HUE036362T2 (hu) | Baktériumtörzseket tartalmazó készítmények | |
| HUE041969T2 (hu) | Baktériumtörzseket tartalmazó készítmények | |
| DK3360558T3 (da) | Sammensætninger omfattende bakteriestammer | |
| HUE048823T2 (hu) | Baktériumtörzseket tartalmazó készítmények | |
| HUE058252T2 (hu) | Baktériumtörzseket tartalmazó készítmények | |
| ME03563B (me) | Kompozicije koje sadrže bakterijske sojeve | |
| HUE046681T2 (hu) | Baktériumtörzseket tartalmazó készítmények | |
| SG11201405829WA (en) | Compositions comprising cocktails of antibacterial phages and uses thereof for the treatment of bacterial infections | |
| DK3074027T3 (da) | Synergistiske bakteriesammensætninger og fremgangsmåder til fremstilling og anvendelse heraf | |
| DK3346008T3 (da) | Rekombinante mikroorganismer og anvendelser deraf | |
| HUE059033T2 (hu) | Benzoxaborol-származékok bakteriális fertõzések kezelésére | |
| BR112015009718A2 (pt) | composição de matéria e artigo. | |
| FR2997014B1 (fr) | Composition sterile dermo-injectable | |
| EP2475377A4 (en) | NOVEL BACTERIOPHAGE AND ANTIBACTERIAL COMPOSITION THEREWITH | |
| DK2961835T3 (da) | Ny bakteriophag og antibakteriel sammensætning omfattende samme | |
| EP2655603A4 (en) | NOVEL BACTERIOPHAGE AND ANTIBACTERIAL COMPOSITION THEREWITH | |
| DK2861573T3 (da) | Oxathiazin-derivater som antibakterielle og anticancer-stoffer | |
| PH12014500586A1 (en) | Novel bacteriophage and antibacterial composition comprising the same | |
| DK2547361T3 (da) | Bakterielle vaccinekomponenter fra staphylococcus aureus og anvendelser deraf | |
| EP2995200A4 (en) | Sterilization composition with synergism | |
| ZA201503474B (en) | Compositions and methods for treating bacterial infections | |
| EP2851085A4 (en) | STERILIZED COMPOSITION | |
| FI20125070L (fi) | Erotinväännin ja erotin |